{"id":8748,"date":"2025-10-08T17:18:09","date_gmt":"2025-10-08T09:18:09","guid":{"rendered":"https:\/\/regask.com\/?p=8748"},"modified":"2025-10-15T14:42:26","modified_gmt":"2025-10-15T06:42:26","slug":"les-regulateurs-mondiaux-confirment-labsence-de-lien-entre-lutilisation-du-paracetamol-pendant-la-grossesse-et-lautisme-chez-les-enfants","status":"publish","type":"post","link":"https:\/\/regask.com\/fr\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\/","title":{"rendered":"Les r\u00e9gulateurs mondiaux confirment l&#039;absence de lien entre le parac\u00e9tamol et l&#039;ibuprof\u00e8ne."},"content":{"rendered":"<p>Entre <strong>23-26 septembre 2025<\/strong>, plusieurs autorit\u00e9s sanitaires, dont celle de Singapour <strong>Autorit\u00e9 des sciences de la sant\u00e9 (HSA)<\/strong>, L&#039;Australie <strong>Administration des produits th\u00e9rapeutiques (TGA)<\/strong>, La France <strong>ANSM<\/strong>, du Chili <strong>FAI<\/strong>, La Suisse <strong>Swissmedic<\/strong>, du Portugal <strong>Infarmed<\/strong>, l&#039;Espagne <strong>AEMPS<\/strong>, La Belgique <strong>AFMPS\/EMA<\/strong>, <strong>La FDA tha\u00eflandaise<\/strong>, et <strong>Minist\u00e8re de la Sant\u00e9 de la Nouvelle-Z\u00e9lande (MOH)<\/strong> \u00e9mis des avis coordonn\u00e9s r\u00e9affirmant la <strong>s\u00e9curit\u00e9 de l&#039;utilisation du parac\u00e9tamol (ac\u00e9taminoph\u00e8ne) pendant la grossesse<\/strong>.<\/p>\n<p>Bien que ces avis r\u00e9pondent au d\u00e9bat public en cours sur les liens possibles entre l\u2019exposition pr\u00e9natale au parac\u00e9tamol et <strong>troubles du d\u00e9veloppement neurologique<\/strong> tel que <strong>troubles du spectre autistique (TSA)<\/strong> et <strong>trouble du d\u00e9ficit de l&#039;attention\/hyperactivit\u00e9 (TDAH)<\/strong>, tous les r\u00e9gulateurs, \u00e0 l&#039;exception du FAI du Chili, ont conclu que <strong>les preuves scientifiques actuelles ne soutiennent pas une relation causale<\/strong>.<\/p>\n<div class=\"row\"  id=\"row-2010798433\">\n\n\t<div id=\"col-310572845\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3><strong>Mises \u00e0 jour r\u00e9glementaires par pays<\/strong><\/h3>\n\t<div id=\"gap-927403534\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-927403534 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><a href=\"https:\/\/www.hsa.gov.sg\/\"><strong>Singapour (HSA) :<\/strong><\/a> Publi\u00e9 le <strong>26 septembre 2025<\/strong>, l&#039;avis de la HSA indiquait que <strong>aucune preuve \u00e9tablie ne lie l&#039;utilisation du parac\u00e9tamol pendant la grossesse \u00e0 l&#039;autisme ou \u00e0 d&#039;autres troubles neurologiques chez les enfants<\/strong>. Le parac\u00e9tamol reste recommand\u00e9 pour la gestion de la douleur et de la fi\u00e8vre lorsque cela est cliniquement n\u00e9cessaire. L&#039;HSA continue <strong>surveillance de la s\u00e9curit\u00e9 post-commercialisation<\/strong> et une collaboration internationale pour examiner les donn\u00e9es \u00e9mergentes.<\/p>\n<p><a href=\"https:\/\/www.tga.gov.au\/\"><strong>Australie (TGA) :<\/strong><\/a> \u00a0Sur <strong>23 septembre 2025<\/strong>, la TGA a r\u00e9affirm\u00e9 le parac\u00e9tamol <strong>Classification de la cat\u00e9gorie de grossesse A<\/strong>, indiquant qu&#039;il est sans danger lorsqu&#039;il est utilis\u00e9 conform\u00e9ment aux instructions. Aucun lien de causalit\u00e9 n&#039;a \u00e9t\u00e9 \u00e9tabli entre l&#039;utilisation pr\u00e9natale et l&#039;autisme ou le TDAH. La TGA a soulign\u00e9 <strong>gestion de la fi\u00e8vre et de la douleur maternelles<\/strong> comme essentiel \u00e0 la sant\u00e9 du f\u0153tus et poursuit la pharmacovigilance continue.<\/p>\n<p><a href=\"https:\/\/ansm.sante.fr\/\"><strong>France (ANSM) :<\/strong><\/a> Publi\u00e9 le <strong>25 septembre 2025<\/strong>, L&#039;ANSM a confirm\u00e9 que <strong>le parac\u00e9tamol reste l&#039;analg\u00e9sique et l&#039;antipyr\u00e9tique le plus s\u00fbr pendant la grossesse<\/strong>, avec <strong>Les AINS sont contre-indiqu\u00e9s apr\u00e8s le sixi\u00e8me mois<\/strong> En raison du risque f\u0153tal, l&#039;agence a r\u00e9it\u00e9r\u00e9 l&#039;absence de preuve liant le parac\u00e9tamol \u00e0 des troubles neurologiques.<\/p>\n<p><a href=\"https:\/\/www.ispch.cl\/\"><strong>Chili (FAI)<\/strong><\/a><strong>:<\/strong> Sur <strong>23 septembre 2025<\/strong>, Le FAI a \u00e9mis un avis plus prudent, reconnaissant <strong>r\u00e9sultats non concluants<\/strong> sugg\u00e9rant une possible association entre l&#039;utilisation de parac\u00e9tamol pendant la grossesse et les troubles du d\u00e9veloppement neurologique. L&#039;ISP a not\u00e9 une divergence r\u00e9glementaire, comme <strong>La FDA<\/strong> consid\u00e8re les mises \u00e0 jour des \u00e9tiquettes tout en <strong>EMA<\/strong> et <strong>AEMPS<\/strong> n&#039;ont pas r\u00e9vis\u00e9 leurs directives. L&#039;agence poursuit ses <strong>revue de la litt\u00e9rature mondiale<\/strong> et recommande une surveillance m\u00e9dicale.<\/p>\n<p><a href=\"https:\/\/www.swissmedic.ch\/swissmedic\/en\/home.html\"><strong>Suisse (Swissmedic) :<\/strong><\/a> Publi\u00e9 le <strong>24 septembre 2025<\/strong>, l&#039;avis de Swissmedic s&#039;aligne sur le consensus mondial, confirmant <strong>aucun lien prouv\u00e9 entre le parac\u00e9tamol et l&#039;autisme<\/strong>. Le parac\u00e9tamol reste <strong>autoris\u00e9 pour une utilisation pendant la grossesse<\/strong>, \u00e0 condition de suivre les instructions de la notice.<\/p>\n<p><a href=\"https:\/\/www.infarmed.pt\/\"><strong>Portugal (Infarmed) :<\/strong><\/a> Sur <strong>23 septembre 2025<\/strong>, Infarmed a confirm\u00e9 <strong>aucun changement dans le profil de s\u00e9curit\u00e9 du parac\u00e9tamol<\/strong>, suite \u00e0 l&#039;examen de l&#039;EMA. Il reste <strong>approuv\u00e9 pour une utilisation clinique pendant la grossesse<\/strong>, en mettant l\u2019accent sur les doses minimales efficaces et la dur\u00e9e.<\/p>\n<p><a href=\"https:\/\/www.aemps.gob.es\/la-aemps\/informacion-y-atencion-a-la-ciudadania\/?lang=en\"><strong>Espagne (AEMPS) :<\/strong><\/a> \u00a0\u00c9galement dat\u00e9 <strong>23 septembre 2025<\/strong>, L&#039;AEMPS a r\u00e9affirm\u00e9 que <strong>il n&#039;existe aucune relation de cause \u00e0 effet<\/strong> Comparaison entre le parac\u00e9tamol et l&#039;autisme ou les troubles neurod\u00e9veloppementaux. Les recommandations concernant la posologie et la dur\u00e9e du traitement restent inchang\u00e9es.<\/p>\n<p><strong>Belgique et EMA (<\/strong><a href=\"https:\/\/www.afmps.be\/fr\"><strong>AFMPS<\/strong><\/a><strong>\/<\/strong><a href=\"https:\/\/www.ema.europa.eu\/en\/homepage\"><strong>EMA<\/strong><\/a><strong>): <\/strong>\u00a0Publi\u00e9 conjointement le <strong>23 septembre 2025<\/strong>, l&#039;avis a reconfirm\u00e9 que le parac\u00e9tamol reste <strong>le traitement de premier choix contre la douleur et la fi\u00e8vre pendant la grossesse<\/strong>, citant des \u00e9tudes \u00e0 grande \u00e9chelle montrant <strong>aucun lien avec le TSA ou le TDAH<\/strong>. La surveillance de la s\u00e9curit\u00e9 \u00e0 long terme se poursuivra.<\/p>\n<p><a href=\"https:\/\/en.fda.moph.go.th\/\"><strong>Tha\u00eflande (FDA)<\/strong><\/a><strong>: <\/strong>\u00a0Le 25 septembre 2025, la FDA tha\u00eflandaise a pr\u00e9cis\u00e9 que <strong>aucune preuve claire ne soutient ces affirmations<\/strong> reliant la prise de parac\u00e9tamol pendant la grossesse \u00e0 l&#039;autisme. Le parac\u00e9tamol reste le <strong>m\u00e9dicament de premier choix<\/strong> Pour soulager la douleur et la fi\u00e8vre chez la femme enceinte, lorsqu&#039;il est utilis\u00e9 de mani\u00e8re responsable. La FDA a cit\u00e9 une \u00e9tude su\u00e9doise de 2024 et des analyses internationales de la FDA am\u00e9ricaine, de la MHRA britannique et de l&#039;EMA europ\u00e9enne, soulignant <strong>dose efficace la plus faible, dur\u00e9e la plus courte<\/strong>, et consultation professionnelle.<\/p>\n<p><a href=\"https:\/\/www.health.govt.nz\/\"><strong>Nouvelle-Z\u00e9lande (MOH \/ Medsafe) :<\/strong><\/a> Publi\u00e9 le 26 septembre 2025, le minist\u00e8re de la Sant\u00e9 a r\u00e9affirm\u00e9 que <strong>le parac\u00e9tamol est l&#039;option la plus s\u00fbre pour traiter la douleur et la fi\u00e8vre pendant la grossesse<\/strong>, avec <strong>aucun lien de causalit\u00e9 avec l&#039;autisme<\/strong> bas\u00e9 sur des donn\u00e9es scientifiques de haute qualit\u00e9. <a href=\"https:\/\/www.medsafe.govt.nz\/\">Medsafe<\/a> continue <strong>pharmacovigilance en cours<\/strong> et encourage la consultation avec des professionnels de la sant\u00e9 pour obtenir des conseils sur les m\u00e9dicaments.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-310572845 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-490116994\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3>Pourquoi c&#039;est important<\/h3>\n\t<div id=\"gap-1212961784\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1212961784 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Ces avis coh\u00e9rents entre les autorit\u00e9s r\u00e9glementaires mondiales renforcent l&#039;harmonisation r\u00e9glementaire concernant le profil de s\u00e9curit\u00e9 du parac\u00e9tamol pendant la grossesse. En maintenant les recommandations actuelles, les autorit\u00e9s r\u00e9glementaires garantissent clart\u00e9 et continuit\u00e9 pour les professionnels de sant\u00e9 et les fabricants de produits pharmaceutiques, tout en minimisant la confusion pour les consommateurs.<\/p>\n<p>Cette communication coordonn\u00e9e souligne \u00e9galement l\u2019importance d\u2019une pharmacovigilance fond\u00e9e sur des donn\u00e9es probantes, r\u00e9duisant ainsi la charge r\u00e9glementaire inutile et maintenant la confiance du public dans les m\u00e9dicaments en vente libre largement utilis\u00e9s.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-490116994 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1728311229\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3>\u00c0 qui s&#039;adresse cette mise \u00e0 jour<\/h3>\n\t<div id=\"gap-1957572435\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1957572435 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Ces avis coh\u00e9rents entre les autorit\u00e9s r\u00e9glementaires mondiales renforcent l&#039;harmonisation r\u00e9glementaire concernant le profil de s\u00e9curit\u00e9 du parac\u00e9tamol pendant la grossesse. En maintenant les recommandations actuelles, les autorit\u00e9s r\u00e9glementaires garantissent clart\u00e9 et continuit\u00e9 pour les professionnels de sant\u00e9 et les fabricants de produits pharmaceutiques, tout en minimisant la confusion pour les consommateurs.<\/p>\n<p>Cette communication coordonn\u00e9e souligne \u00e9galement l\u2019importance d\u2019une pharmacovigilance fond\u00e9e sur des donn\u00e9es probantes, r\u00e9duisant ainsi la charge r\u00e9glementaire inutile et maintenant la confiance du public dans les m\u00e9dicaments en vente libre largement utilis\u00e9s.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1728311229 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-858499684\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3>Prochaines \u00e9tapes pour les parties prenantes<\/h3>\n\t<div id=\"gap-1214816208\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1214816208 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Les \u00e9quipes de r\u00e9glementation et d\u2019\u00e9tiquetage doivent :<\/p>\n<ul>\n<li>Revoir <strong>Informations sur le produit (IP)<\/strong>, <strong>Informations sur les m\u00e9dicaments \u00e0 destination des consommateurs (CMI)<\/strong>, et les notices d\u2019emballage pour assurer la coh\u00e9rence avec les directives nationales mises \u00e0 jour.<\/li>\n<li>Continuer <strong>avis de surveillance<\/strong> de la FDA, de l&#039;EMA, de l&#039;ISP et d&#039;autres agences pour toute donn\u00e9e \u00e9mergente susceptible d&#039;affecter l&#039;\u00e9tiquetage ou la communication des risques.<\/li>\n<li>Aligner <strong>supports de marketing et d&#039;\u00e9ducation des patients<\/strong> avec les recommandations actuelles sur la posologie, la dur\u00e9e et les exigences de consultation m\u00e9dicale.<\/li>\n<\/ul>\n<p>\u00c0 mesure que la surveillance r\u00e9glementaire autour de la sant\u00e9 et de la s\u00e9curit\u00e9 maternelles s\u2019intensifie, la surveillance proactive et l\u2019alignement des documents seront essentiels pour maintenir la conformit\u00e9.<\/p>\n<p>Pour aider les organisations \u00e0 garder une longueur d\u2019avance sur les mises \u00e0 jour mondiales en constante \u00e9volution, <a href=\"https:\/\/regask.com\/fr\/\"><strong>RegASK<\/strong><\/a> fournit des solutions bas\u00e9es sur l&#039;IA et un soutien expert qui suivent, analysent et op\u00e9rationnalisent ces avis r\u00e9glementaires dans toutes les juridictions.<\/p>\n<p><a href=\"https:\/\/regask.com\/fr\/\"><strong>RegASK<\/strong><\/a> est une plateforme leader de veille r\u00e9glementaire et d&#039;orchestration des workflows bas\u00e9e sur l&#039;IA agentique. Elle permet aux organisations internationales des secteurs hautement r\u00e9glement\u00e9s, notamment les biens de consommation et les sciences de la vie, de s&#039;adapter proactivement \u00e0 des environnements r\u00e9glementaires complexes. En associant une IA agentique avanc\u00e9e \u00e0 des experts en la mati\u00e8re, RegASK fournit des informations pr\u00e9dictives, exploitables et rapides, ainsi qu&#039;une automatisation compl\u00e8te, rationalisant ainsi les processus de conformit\u00e9, att\u00e9nuant les risques et acc\u00e9l\u00e9rant l&#039;acc\u00e8s au march\u00e9 dans plus de 140 pays. <a href=\"https:\/\/regask.com\/fr\/produit\/\"><strong>En savoir plus<\/strong><\/a><strong> ou <\/strong><a href=\"https:\/\/regask.com\/fr\/reserver-une-demo\/\"><strong>r\u00e9servez une d\u00e9mo maintenant.<\/strong><\/a><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-858499684 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n<div class=\"row\"  id=\"row-1023547697\">\n\n\t<div id=\"col-1721309050\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"is-divider divider clearfix\" style=\"margin-top:2em;margin-bottom:2em;max-width:20%;height:1px;background-color:#a5acd9;\"><\/div>\n<h3>FAQ<\/h3>\n\t<div id=\"gap-263048475\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-263048475 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<h4>Quelle est la position r\u00e9glementaire mondiale actuelle sur l\u2019utilisation du parac\u00e9tamol pendant la grossesse ?<\/h4>\n\t<div id=\"gap-1263377773\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1263377773 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Les autorit\u00e9s r\u00e9glementaires de Singapour, d\u2019Australie, de France, de Suisse, du Portugal, d\u2019Espagne, de Belgique, du Royaume-Uni et de l\u2019UE ont confirm\u00e9 que le parac\u00e9tamol reste s\u00fbr \u00e0 utiliser pendant la grossesse lorsque cela est cliniquement n\u00e9cessaire, sans lien prouv\u00e9 avec l\u2019autisme ou le TDAH.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1721309050 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1829837643\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>Quels pays ont exprim\u00e9 leur prudence concernant le parac\u00e9tamol et les troubles neurod\u00e9veloppementaux ?<\/h4>\n\t<div id=\"gap-2026790269\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-2026790269 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>L&#039;ISP chilien a appel\u00e9 \u00e0 une utilisation prudente dans l&#039;attente d&#039;un examen plus approfondi, citant des r\u00e9sultats non concluants, tandis que la FDA am\u00e9ricaine envisage de mettre \u00e0 jour les \u00e9tiquettes pour refl\u00e9ter le d\u00e9bat scientifique en cours.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1829837643 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1546907745\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>Pourquoi les AINS sont-ils contre-indiqu\u00e9s pendant la grossesse ?<\/h4>\n\t<div id=\"gap-778918160\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-778918160 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Selon l&#039;ANSM fran\u00e7aise, les AINS tels que l&#039;ibuprof\u00e8ne, le k\u00e9toprof\u00e8ne et l&#039;aspirine sont contre-indiqu\u00e9s apr\u00e8s le sixi\u00e8me mois de grossesse en raison de risques f\u0153taux graves, faisant du parac\u00e9tamol l&#039;alternative privil\u00e9gi\u00e9e.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1546907745 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1352681028\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>Comment RegASK peut-il aider les \u00e9quipes r\u00e9glementaires \u00e0 g\u00e9rer l\u2019\u00e9volution des avis de s\u00e9curit\u00e9 des m\u00e9dicaments ?<\/h4>\n\t<div id=\"gap-564233440\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-564233440 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><a href=\"https:\/\/regask.com\/fr\/\">RegASK<\/a> permet aux organisations pharmaceutiques et de soins de sant\u00e9 de <strong>suivre les mises \u00e0 jour r\u00e9glementaires mondiales<\/strong>, \u00e9valuer l&#039;impact et automatiser les flux de travail de conformit\u00e9 en garantissant que les informations sur les produits, l&#039;\u00e9tiquetage et la communication restent align\u00e9s dans toutes les juridictions.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1352681028 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Between September 23\u201326, 2025, multiple health authorities, including Singapore\u2019s Health Sciences Authority (HSA), Australia\u2019s Therapeutic Goods Administration (TGA), France\u2019s ANSM, Chile\u2019s ISP, Switzerland\u2019s Swissmedic, Portugal\u2019s Infarmed, Spain\u2019s AEMPS, Belgium\u2019s AFMPS\/EMA, Thailand\u2019s FDA, and New Zealand\u2019s Ministry of Health (MOH) issued coordinated advisories reaffirming the safety of paracetamol (acetaminophen) use during pregnancy. While these advisories address&#8230;<\/p>","protected":false},"author":32,"featured_media":8749,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[33,35],"tags":[],"class_list":["post-8748","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-pharma-biotech-latest-insights"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.3 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Global Regulators Confirm No Link Between Paracetamol Use in Pregnancy and Autism in Children<\/title>\n<meta name=\"description\" content=\"Global regulators confirm no link between paracetamol use in pregnancy and autism in children. Learn more about the findings.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/fr\/les-regulateurs-mondiaux-confirment-labsence-de-lien-entre-lutilisation-du-paracetamol-pendant-la-grossesse-et-lautisme-chez-les-enfants\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global Regulators Confirm No Link Between Paracetamol Use in Pregnancy and Autism in Children\" \/>\n<meta property=\"og:description\" content=\"Global regulators confirm no link between paracetamol use in pregnancy and autism in children. Learn more about the findings.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/fr\/les-regulateurs-mondiaux-confirment-labsence-de-lien-entre-lutilisation-du-paracetamol-pendant-la-grossesse-et-lautisme-chez-les-enfants\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-08T09:18:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-15T06:42:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2025\/10\/global-regulators-confirm-no-link-between-paracetamol-use-pregnancy-autism-children.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Hannah Nordin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Hannah Nordin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\\\/\"},\"author\":{\"name\":\"Hannah Nordin\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/3a8aaee2c7585284f97ec9e038e36b65\"},\"headline\":\"Global Regulators Confirm No Link Between Paracetamol U&hellip;\",\"datePublished\":\"2025-10-08T09:18:09+00:00\",\"dateModified\":\"2025-10-15T06:42:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\\\/\"},\"wordCount\":1178,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/global-regulators-confirm-no-link-between-paracetamol-use-pregnancy-autism-children.png\",\"articleSection\":[\"Regulatory News\",\"Pharma and Biotech\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\\\/\",\"name\":\"Global Regulators Confirm No Link Between Paracetamol Use in Pregnancy and Autism in Children\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/global-regulators-confirm-no-link-between-paracetamol-use-pregnancy-autism-children.png\",\"datePublished\":\"2025-10-08T09:18:09+00:00\",\"dateModified\":\"2025-10-15T06:42:26+00:00\",\"description\":\"Global regulators confirm no link between paracetamol use in pregnancy and autism in children. Learn more about the findings.\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/regask.com\\\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/global-regulators-confirm-no-link-between-paracetamol-use-pregnancy-autism-children.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/global-regulators-confirm-no-link-between-paracetamol-use-pregnancy-autism-children.png\",\"width\":800,\"height\":600,\"caption\":\"Global Regulators Confirm No Link Between Paracetamol Use Pregnancy Autism Children\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"Empowering Smarter Regulatory Decisions\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\",\"name\":\"RegASK\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"width\":401,\"height\":401,\"caption\":\"RegASK\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RegASKRegulatoryAffairs\\\/\",\"https:\\\/\\\/x.com\\\/ASKRegASK\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/RegASK\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@RegASK\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/3a8aaee2c7585284f97ec9e038e36b65\",\"name\":\"Hannah Nordin\",\"sameAs\":[\"https:\\\/\\\/regask.com\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Les autorit\u00e9s r\u00e9glementaires mondiales confirment l&#039;absence de lien entre l&#039;utilisation du parac\u00e9tamol pendant la grossesse et l&#039;autisme chez les enfants.","description":"Les autorit\u00e9s r\u00e9glementaires mondiales confirment l&#039;absence de lien entre la prise de parac\u00e9tamol pendant la grossesse et l&#039;autisme chez l&#039;enfant. En savoir plus sur ces r\u00e9sultats.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/fr\/les-regulateurs-mondiaux-confirment-labsence-de-lien-entre-lutilisation-du-paracetamol-pendant-la-grossesse-et-lautisme-chez-les-enfants\/","og_locale":"fr_FR","og_type":"article","og_title":"Global Regulators Confirm No Link Between Paracetamol Use in Pregnancy and Autism in Children","og_description":"Global regulators confirm no link between paracetamol use in pregnancy and autism in children. Learn more about the findings.","og_url":"https:\/\/regask.com\/fr\/les-regulateurs-mondiaux-confirment-labsence-de-lien-entre-lutilisation-du-paracetamol-pendant-la-grossesse-et-lautisme-chez-les-enfants\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2025-10-08T09:18:09+00:00","article_modified_time":"2025-10-15T06:42:26+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2025\/10\/global-regulators-confirm-no-link-between-paracetamol-use-pregnancy-autism-children.png","type":"image\/png"}],"author":"Hannah Nordin","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Hannah Nordin","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\/#article","isPartOf":{"@id":"https:\/\/regask.com\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\/"},"author":{"name":"Hannah Nordin","@id":"https:\/\/regask.com\/#\/schema\/person\/3a8aaee2c7585284f97ec9e038e36b65"},"headline":"Global Regulators Confirm No Link Between Paracetamol U&hellip;","datePublished":"2025-10-08T09:18:09+00:00","dateModified":"2025-10-15T06:42:26+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\/"},"wordCount":1178,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/10\/global-regulators-confirm-no-link-between-paracetamol-use-pregnancy-autism-children.png","articleSection":["Regulatory News","Pharma and Biotech"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/regask.com\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\/","url":"https:\/\/regask.com\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\/","name":"Les autorit\u00e9s r\u00e9glementaires mondiales confirment l&#039;absence de lien entre l&#039;utilisation du parac\u00e9tamol pendant la grossesse et l&#039;autisme chez les enfants.","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/10\/global-regulators-confirm-no-link-between-paracetamol-use-pregnancy-autism-children.png","datePublished":"2025-10-08T09:18:09+00:00","dateModified":"2025-10-15T06:42:26+00:00","description":"Les autorit\u00e9s r\u00e9glementaires mondiales confirment l&#039;absence de lien entre la prise de parac\u00e9tamol pendant la grossesse et l&#039;autisme chez l&#039;enfant. En savoir plus sur ces r\u00e9sultats.","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/regask.com\/global-regulators-confirm-no-link-between-paracetamol-use-in-pregnancy-and-autism-in-children\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2025\/10\/global-regulators-confirm-no-link-between-paracetamol-use-pregnancy-autism-children.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/10\/global-regulators-confirm-no-link-between-paracetamol-use-pregnancy-autism-children.png","width":800,"height":600,"caption":"Global Regulators Confirm No Link Between Paracetamol Use Pregnancy Autism Children"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Favoriser des d\u00e9cisions r\u00e9glementaires plus intelligentes","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/regask.com\/#organization","name":"RegASK","url":"https:\/\/regask.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","width":401,"height":401,"caption":"RegASK"},"image":{"@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","https:\/\/x.com\/ASKRegASK","https:\/\/www.linkedin.com\/company\/RegASK\/","https:\/\/www.youtube.com\/@RegASK"]},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/3a8aaee2c7585284f97ec9e038e36b65","name":"Hannah Nordin","sameAs":["https:\/\/regask.com"]}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/8748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/comments?post=8748"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/8748\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media\/8749"}],"wp:attachment":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media?parent=8748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/categories?post=8748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/tags?post=8748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}